Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A

Area of Science:

• Hematology
• Coagulation Disorders
• Clinical Research

Background:

• Hemophilia A (HA) severity correlates with factor VIII (FVIII) deficiency.
• The precise FVIII level for preventing joint bleeds in HA patients is not well-defined.

Purpose of the Study:

• To determine the minimum plasma factor VIII (FVIII) level required to prevent joint bleeds in individuals with hemophilia A.
• To establish target FVIII levels for effective prophylactic treatment strategies.

Main Methods:

• Retrospective analysis of 270 adult male patients with mild congenital hemophilia A.
• Patients received on-demand treatment and had no history of FVIII inhibitors.
• Statistical analysis to correlate FVIII levels with annualized joint bleeding rates (AJBR).

Main Results:

• A history of joint bleeds was reported in 37% of patients.
• Each 1 IU/dL increase in FVIII correlated with a 6% reduction in AJBR and 11% in spontaneous AJBR.
• Minimum FVIII levels identified: 19.2 IU/dL for any joint bleeds and 17.7 IU/dL for spontaneous joint bleeds.

Conclusions:

• Identified minimum FVIII levels (19.2 IU/dL and 17.7 IU/dL) to prevent total and spontaneous joint bleeds in mild HA.
• Findings have implications for designing prophylactic therapies, including gene therapy, for hemophilia A patients.